Pearl Steinzor

Coverage from the Tampa Regional session of the Institute for Value-Based Medicine.

Neha Kashalikar, PharmD, director of strategic pharmacy consulting at MassHealth, breaks down the outcome measures often used in pharmacy and medical claims to evaluate the performance of value-based contracts.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of once-daily icotrokinra (JNJ-2113) in adolescents with moderate to severe plaque psoriasis.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, shares how health care leaders are advancing value-based care through improved data strategies, real-world evidence, and AI-driven efficiencies, without losing the human touch.

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy, highlights key policy updates that are impacting managed care pharmacy.

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Attendees of the Academy of Managed Care Pharmacy annual meeting share explain what draws them to the conference year after year.

Patient navigation and mailed outreach improved colorectal cancer screening rates in rural clinics, but follow-up colonoscopy participation remains low.

Biologics for psoriasis had lower drug survival in women compared with men, according to one study.

Nearly 1 in 9 adults are living with diabetes, according to new research by the International Diabetes Federation.

As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, discusses the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and Medicaid committees.

Sam Peasah, PhD, MBA, RPh, director of High-Value Health Care Value-Based Pharmacy Initiatives at UPMC Health Plan, shares findings from a study on the cost impact of achieving 80% adherence to newer antidiabetic agents.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses the evolving role pharmacy benefit managers (PBMs) play in addressing payer, provider, and patient needs.

Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth, shares key components that makes a value-based contract successful.

Adam Colborn, JD, associate vice president for congressional affairs, AMCP, discusses key regulatory factors that managed care professionals must consider when implementing artificial intelligence (AI) in practice.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug survival of almost 3 years.

Susan Cantrell, CEO of the Academy of Managed Care Pharmacy, breaks down some of the key conference topics that will be discussed at this year's meeting.

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, highlights upcoming discussions on patient engagement, formulary management, and policy changes, including the Inflation Reduction Act.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety and efficacy findings.

A meta-analysis finds no significant increase in suicide-related events with glucagon-like peptide-1 receptor agonists.

Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint inhibitor–based therapy.

Public health official warns the expanding measles outbreak could last a year.

Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care needs and physical activity barriers for individuals with myotonic dystrophy.

Biologics targeting interleukin (IL)-12, IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

This new study has found perceived discrimination in health care leads to delayed visits, especially among younger and minority patients.

Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.